Genprex enters exclusive license with Univ of Michigan for Reqorsa in ALK+ lung cancer

Genprex, Inc.

License grants Genprex worldwide exclusive rights to University of Michigan patents for Reqorsa gene therapy combined with ALK-inhibitors for ALK-EML4 positive NSCLC.
Preclinical data at AACR April 2024 showed Reqorsa induced apoptosis in alectinib-resistant EML4-ALK positive NSCLC cell lines.
Researchers believe results support further clinical study of Reqorsa as an anti-ALK NSCLC treatment strategy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.